Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rosuvastatin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR known ✓ | P04035 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | PDE6D | O43924 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.84 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.84 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.83 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.83 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.83 |
| ▸ | ESR1 | P03372 | 1/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.58 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.58 |
| ▸ | PDE4A | P27815 | 1/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rosuvastatin SCHEMBL28393539 | 1.00 | HMGCR (1.00) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| Rosuvastatin SCHEMBL240432 | 1.00 | HMGCR (1.00) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| Rosuvastatin SCHEMBL32686257 | 1.00 | HMGCR (1.00) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| Rosuvastatin SCHEMBL2520 | 1.00 | HMGCR (1.00) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| Rosuvastatin SCHEMBL3938301 | 1.00 | HMGCR (1.00) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| Rosuvastatin SCHEMBL154400 | 1.00 | HMGCR (1.00) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| Rosuvastatin SCHEMBL16995485 | 1.00 | HMGCR (1.00) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| Rosuvastatin SCHEMBL240433 | 1.00 | HMGCR (1.00) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| Rosuvastatin SCHEMBL8268193 | 1.00 | HMGCR (1.00) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| Rosuvastatin SCHEMBL29722976 | 1.00 | HMGCR (1.00) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 10973 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117890509-B | Ezetimibe rosuvastatin calcium tablet dissolution curve detection method with distinguishing force | 江西施美药业股份有限公司 | 2026-05-19 | — | — | CN | claimed |
| CN-122005470-A | Preparation method of rosuvastatin calcium tablet | 琼海市人民医院 | 2026-05-12 | — | — | CN | claimed |
| US-12622895-B2 | Anti-neurodegenerative combinations and use for treatment of neurodegenerative diseases | ALTO NEUROSCIENCE, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-20260115142-A1 | PHARMACEUTICAL COMPOSITION COMPRISING ROSUVASTATIN AND ACETYLSALICYLIC ACID, PROCESS FOR PREPARING THE SAME, AND USES THEREOF | LABORATORIOS SILANES S A DE C V (MX) | 2026-04-30 | — | — | US | claimed |
| EP-4717256-A1 | PHARMACEUTICAL COMPOSITION COMPRISING ROSUVASTATIN AND OMEGA-3, PROCESS FOR PREPARING THE SAME, AND USES THEREOF | Laboratorios Silanes, S.A. de C.V. (MX) | 2026-04-01 | — | — | EP | claimed |
| EP-4710920-A1 | PHARMACEUTICAL COMPOSITION COMPRISING COMBINATION OF AMLODIPINE, RAMIPRIL AND ROSUVASTATIN | Adamed Pharma S.A. (PL) | 2026-03-18 | — | — | EP | claimed |
| EP-4678233-A2 | PHARMACEUTICAL COMPOSITION COMPRISING HMG-COA REDUCTASE INHIBITORS AND FENOFIBRATE | Intas Pharmaceuticals Ltd. (IN) | 2026-01-14 | — | — | EP | claimed |
| US-20250366785-A1 | METHODS FOR PROCESSING, ENRICHMENT, DELIVERY, FORMULATION, AND UPTAKE FOR SUPPLEMENTS AND PHARMACEUTICALS | VAN DE CASTEELE RUSSELL (US) | 2025-12-04 | — | — | US | claimed |
| US-20250332254-A1 | METHODS FOR TREATING PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA | REGENERON PHARMA (US) | 2025-10-30 | — | — | US | claimed |
| EP-4636093-A1 | TARGETING MAPK-ERK PATHWAY FOR ENHANCING NUCLEIC ACID DELIVERY | Paul-Ehrlich-Institut, Bundesinstitut für Impfstoffe und biomedizinische Arzneimittel (DE) | 2025-10-22 | — | — | EP | claimed |
| EP-1465616-A1 | TREATMENT OF STATIN SIDE EFFECTS USING URIDINE DERIVATIVES | Magral Limited (AU) | 2004-10-13 | — | — | EP | claimed |
| US-20040176615-A1 | Processes for preparing calcium salt forms of statins | NIDDAM-HILDESHEIM VALERIE (IL) | 2004-09-09 | — | — | US | claimed |
| US-6777552-B2 | FROM AN ESTER DERIVATIVE OR PROTECTED ESTER DERIVATIVE OF THE STATIN BY USING CALCIUM HYDROXIDE | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2004-08-17 | — | — | US | claimed |
| EP-1425287-A1 | PROCESSES FOR PREPARING CALCIUM SALT FORMS OF STATINS | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-06-09 | — | — | EP | claimed |
| WO-2004027075-A2 | CHEMOENZYMATIC METHODS FOR THE SYNTHESIS OF STATINS AND STAIN INTERMEDIATES | DIVERSA CORPORATION (US) | 2004-04-01 | — | — | WO | claimed |
| US-20030171407-A1 | Composition for reducing blood glucose and cholesterol | UPSHER-SMITH LABORATORIES, INC. | 2003-09-11 | — | — | US | claimed |
| WO-2003061663-A1 | USE OF BENZOTHIAZEPINES HAVING ACTIVITY AS INHIBITORS OF ILEAL BILE ACID TRANSPORT FOR REDUCING CHOLESTEROLOLEMIA | ASTRAZENECA AB (SE) | 2003-07-31 | — | — | WO | claimed |
| US-20030114685-A1 | Processes for preparing calcium salt forms of statins | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2003-06-19 | — | — | US | claimed |
| WO-2003049730-A1 | TREATMENT OF STATIN SIDE EFFECTS USING URIDINE DERIVATIVES | MAGRAL LIMITED (AU) | 2003-06-19 | — | — | WO | claimed |
| WO-2003016317-A1 | PROCESSES FOR PREPARING CALCIUM SALT FORMS OF STATINS | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2003-02-27 | — | — | WO | claimed |